Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | TRPM5 | Q9NZQ8 | 2/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6959841 | 0.79 | SLC6A4 (0.50) | TRPM5ADRA2AADRA2BADRA2CSLC6A4 | |
| SCHEMBL16595181 | 0.76 | TRPM5 (0.40) | FYNTRPM5SLC6A4CYP19A1CYP11B2 | |
| SCHEMBL21916247 | 0.76 | FYN (0.42) | FYNADRA2AADRA2BADRA2CSLC6A4 | |
| SCHEMBL6953435 | 0.76 | FYN (0.42) | FYNCYP19A1CYP11B2 | |
| SCHEMBL23856716 | 0.74 | DYRK1A (0.36) | FYNTRPM5CYP19A1CYP11B2 | |
| SCHEMBL29203082 | 0.73 | — | — | |
| SCHEMBL6958835 | 0.72 | FYN (0.33) | FYN | |
| SCHEMBL6954947 | 0.71 | DRD2 (0.46) | TRPM5CYP19A1 | |
| SCHEMBL16595259 | 0.71 | FYN (0.34) | FYNCYP19A1CYP11B2 | |
| SCHEMBL3149281 | 0.71 | ALDH1A1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674507-B2 | Pyran-dioxane derivatives, and the use thereof in liquid-crystalline media | MERCK PATENT GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| US-7674507-B2 | Pyran-dioxane derivatives, and the use thereof in liquid-crystalline media | MERCK PATENT GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| US-20080193682-A1 | Pyran-Dioxane Derivatives, and the Use Thereof in Liquid-Crystalline Media | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080193682-A1 | Pyran-Dioxane Derivatives, and the Use Thereof in Liquid-Crystalline Media | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| WO-2008034511-A1 | INDANE COMPOUNDS FOR USE AS COMPONENTS OF LIQUID CRYSTAL MEDIA | MERCK PATENT GMBH (DE) | 2008-03-27 | — | — | WO | disclosed |
| EP-1010693-B1 | Imidazoline derivatives, preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-09-24 | — | — | EP | disclosed |
| US-6127396-A | Imidazoline compounds | ADIR ET COMPAGNIE (FR) | 2000-10-03 | — | — | US | disclosed |
| EP-1010693-A1 | Imidazoline derivatives, preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2000-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193682-A1 | Pyran-Dioxane Derivatives, and the Use Thereof in Liquid-Crystalline Media | PYCARD, NLRP3, NLRP1 | FYN 168/4885APLNR 1450/4885TRPM5 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.